| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA396: Trametinib in combination with dabrafenib for treating unresectable or metastatic melanoma |
|
Medicine details |
|
| Medicine name | dabrafenib (Tafinlar®) |
| Formulation | 50 mg, 75 mg capsule |
| Reference number | 2896 |
| Indication | In combination with trametinib for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation |
| Company | Novartis Pharmaceuticals UK Ltd |
| BNF chapter | Malignant disease & immunosuppression |
| Assessment type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 13/11/2015 |
| NICE guidance | TA396: Trametinib in combination with dabrafenib for treating unresectable or metastatic melanoma |